1World Health Organization. Top ten causes of death. Geneva.. World Health Organization 2011. Available from : http ://www. who. int/ me- diacentre/factsheets/fs310. 2008. pdf. Accessed December 14,2012.
2Behan MW, Chew DP, Aylward PE. The role of antiplatelet therapy in the secondary prevention of coronary artery disease[J]. Curr Opin Cardiol, 2010, 25(4): 321-328.
3Marczewski MM, Postula M, Kosior D. Novel an tiplatelet agents in the prevention of cardiovascular complications- focus on ticagrelor [J].Vase Health Risk Manag, 2010, 6:419-429.
4Siller-Matula JM, Krumphuber J, Jilma B. Phar- macokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disea- ses[J]. BrJ Pharmacol, 2010, 159(3): 502-517.
5Zhou D, Andersson TB, Grimm SW. In vitro eval- uation of potential drug-drug interactions with ti- cagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics[J]. Drug Metab Dispos, 2011, 39(4): 703-710.
6Teng R, Oliver S, Hayes MA. Absorption, distri- bution, metabolism: and excretion of ticagrelor in healthy subjects[J]. Drug Metab Dispos, 2010, 38(9) : 1514-1521.
7Teng R, Butler K. Pharmacokinetics,pharmacody- namics, tolerability and safety of single ascending doses of ticagrelor,a reversibly binding oral P2Y12 receptor antagonist in healthy subjects[J]. Eur J Clin Pharmacol, 2010, 66(5): 487-496.
8Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and re- sponders and effect of switching therapies:the RE- SPOND study[J]. Circulation, 2010, 121 (10): 1188-1199.
9Husted S, Emanuelsson H, Hepinstall S, et ai. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin [J]. Eur Heart J, 2006, 27(9): 1038-1047.
10Gurbel PA, Bliden KP, Butler K, et al. Random- ized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor ver- sus clopidogrel in patients with stable coronary dis ease: the ONSET/OFFSET study[J]. Circulation, 2009, 120(25): 2577-2585.
